Objective: Palivizumab, a monoclonal antibody against respiratory syncytial virus (RSV), has been demonstrated to be safe and effective in young children, but evidence is lacking as to whether palivizumab is effective in preventing RSV-induced morbidity and mortality in children who are immunosuppressed after bone marrow transplantation (BMT). As a randomized, double-blind, placebo-controlled trial is lacking, we chose to examine this issue with the use of decision analysis methodology.
B
one marrow transplantation (BMT) is being increasingly used as curative therapy for childhood malignant and nonmalignant disorders. Treatment required for successful BMT leads to immunosuppression, which results in an increased susceptibility to opportunistic infections. Pulmonary complications are a significant cause of morbidity and mortality in allogeneic BMT, accounting for 10% to 40% of transplant-related deaths. 1 Pulmonary infections with bacterial, fungal, protozoal, and viral pathogens may lead to severe pulmonary dysfunction, critical illness, and death in this high-risk immunosuppressed population. The most frequent causes of viralinduced respiratory failure include adenovirus, influenza A, influenza B, parainfluenza, and respiratory syncytial virus (RSV). In the post-BMT population, infection with RSV was found in over one-quarter of patients with documented pulmonary infectious complications. 2 RSV is the most common identified cause of lower respiratory tract (LRT) infections in infants and children. 3, 4 Children with chronic lung disease of prematurity, congenital heart disease, specifically cyanotic heart disease, or underlying congenital or pharmacologically induced immunosuppression are considered high risk for developing severe RSV LRT illness. Recently palivizumab, a monoclonal antibody against RSV, has been demonstrated, in 2 randomized placebo-controlled trials, to be safe and effective in 2 distinct populations of these high-risk subjects. In the IMpact-RSV trial, prophylaxis with palivizumab decreased RSV-related hospitalizations by 55% in infants with preterm birth or chronic lung disease. 5 In a separate clinical trial of children with hemodynamically significant heart disease, subjects who received monthly palivizumab had a 45% decrease in RSV-related hospitalizations. 6 Based primarily on these 2 large, well-conducted trials, the American Academy of Pediatrics (AAP) Committee on Infectious Diseases has developed a list of high-risk patients in which RSV prophylaxis is recommended. 7 This list includes infants with chronic lung disease, infants born less than 32 weeks gestation regardless of underlying lung disease, and infants with hemodynamically significant heart disease. This statement specifically mentions that RSV prophylaxis has not been studied in immunocompromised children, but that these children may benefit from palivizumab. 7 On the basis of the above studies and the AAP recommendations, it is clear that evidence is lacking as to whether palivizumab is effective in preventing RSVinduced morbidity and mortality in children who are immunosuppressed after BMT. A randomized, doubleblind, placebo-controlled trial would be the ideal approach to answer this question, but a well-designed study would be costly, may be ethically inappropriate, and would require extensive time to plan, fund, complete, and analyze. Therefore, we chose to examine this issue with the use of decision analysis methodology. This technique permits us to use previously published data to attempt to determine whether monthly RSV prophylaxis with palivizumab in children who have undergone BMT would decrease mortality from RSV LRT infections.
METHODS

Decision Analysis
We used a decision tree to model the strategy of RSV prophylaxis with palivizumab in children within a year after undergoing BMT and compared outcome to children who did not receive prophylaxis (Fig. 1) . A decision tree is a representation of a clinical decision problem. It identifies a potential decision, and then outlines the relevant outcomes on basis of that decision. The tree begins with a hypothetical subject and a decision that is made by the physician caring for that patient. The initial node is termed a ''decision'' node, and the branches that follow that decision node are based on the decision made by the clinician. Branching out further in the decision tree, ''chance'' nodes represent areas of uncertainty that can lead to two or more states of health. The chance of progressing to each of these states of health is determined by probabilities obtained from relevant sources, such as acquired data, the medical literature, or expert panels. The final outcome of the subject is determined at the ''terminal'' node, which can represent a number of outcomes (life expectancy, cost, survival, etc.). Once the nodes and probabilities are completed, the tree is solved mathematically by computing the expected values of the treatment decisions. As the model is folded back, the branch from the decision node that leads to the more favorable expected outcome is the preferred choice. As many of the probabilities are based on estimates that may not be exactly precise for the target subject, each probability undergoes an independent sensitivity analysis to determine the robustness of the results under a range of biologically plausible probabilities.
In our model, the subject is a pediatric patient who has undergone BMT within the past year, and is approaching the winter season and the associated high prevalence of RSV. At the decision node (Fig. 1) there are 2 possible choices that the clinician must decide between: either administer palivizumab in monthly injections throughout the winter months or do not administer palivizumab. The chance nodes that follow the decision node represent uncertainties that may occur in the subject after the decision has been made. In our model, the chance nodes are identical for each arm of the decision node. However, the probabilities that each of these specific states of health may occur are different, on basis of the available medical literature. The initial set of chance nodes represents the chance of being exposed and infected with RSV during the winter of study. The second set of chance nodes represent the probabilities of requiring hospitalization on basis of the RSV-induced LRT infection. The final set of chance nodes pertain to the chance of mortality specifically owing to RSV infection. The terminal nodes in our model are categorical: survival or death.
Assumptions
To simplify our model, we made several assumptions: we assumed that the effectiveness of palivizumab in BMT patients is similar to other high-risk populations in which it has been studied; we assumed that the rate of exposure to RSV in the set of children under study was the same as the overall population of children; we assumed that the criteria for hospitalization of an infected child would be the same independent of receiving palivizumab (as would occur in a double-blind trial); and we assumed that children who were never hospitalized would not experience an RSV-related death, on the basis of the fact that our area of interest was mortality related specifically to RSV disease, and not to other causes of mortality in this population, which we could assume will be equal in both groups of study.
Probabilities Table 1 demonstrates the baseline probabilities that were used in our decision analysis model, and also lists the range of biologically plausible values that were used in our sensitivity analyses. Probabilities were determined by formal meta-analysis methods 8 on the basis of the present medical literature. Data were synthesized using a general variance-based method. We assumed events were binomially distributed and computed weighted averages of risks, where weights were the inverse of the variance. There were 5 distinct probabilities that were used for this decision analysis, which were based on data from available literature ( Table 2) .
The first was the probability of being exposed to RSV during a routine winter. This probability was based on the fact that RSV occurs in approximately 50% of children each winter season. 12 Therefore, we used 0.50 as the initial probability. Because this percentage is based on normal healthy children, we chose extreme ranges of 20% to 60% exposure for our sensitivity analysis. The second was the probability of being hospitalized secondary to RSV disease in subjects exposed to RSV who were not treated with palivizumab. This probability was based on 3 distinct studies that found that BMT patients have an approximately 50% risk of developing RSV pneumonia if they have upper respiratory RSV. [9] [10] [11] Assuming that most patients will require hospitalization, meta-analysis techniques determined this probability to be 0.40. The range we chose to determine the sensitivity of this probability was wide, ranging from 20% to 80%, owing to the lack of adequate published data in pediatric BMT patients. The third was the probability of being hospitalized secondary to RSV disease in subjects exposed to RSV who were treated with palivizumab. This was a difficult estimation because there are presently no studies that examine the role of this therapy in this patient population. Therefore, we chose to use the efficacy of this therapy in welldesigned clinical trials in other high-risk populations. In infants who received monthly palivizumab, there was a 55% reduction in the requirement for hospitalization. 5 In a separate clinical trial, subjects who received monthly palivizumab had a 45% decrease in RSV-related hospitalizations. 6 On the basis of these reports, meta-analysis methods determined a 49% reduction in hospitalizations compared with the probability of hospitalization in subjects not treated with RSV prophylaxis. Given the 0.4 probability of hospitalizations in subjects not treated, we assigned a 0.2 probability of hospitalization with palivizumab. To be consistent, we kept the range of values examined to determine sensitivity at 50% of the range for nontreated patients: 0.1 to 0.4. The fourth probability required was the rate of survival in BMT patients hospitalized with RSV LRT infections who did not receive palivizumab. In adult subjects with RSV pneumonia, 3 studies report that there is a 50% to 80% mortality rate. [9] [10] [11] Because mortality in pediatric patients is limited, we performed a meta-analysis with this adult data to assign a mortality rate of 69%, thus leading to a baseline probability of survival of 0.31. Because this probability is based on limited data, the sensitivity analysis was performed across a wide range of survival in these subjects, ranging from 10% to 90%. The final probability to assign was the survival rate of BMT subjects who were hospitalized with RSV LRT infections and who received palivizumab. In the previously mentioned studies, 5, 6 there was not a statistically significant difference in mortality between the treated and untreated groups. Therefore, we chose to assign the same probabilities of survival in this treated group as we assigned to the untreated group. This was a baseline survival of 0.31, with a broad range of survival from 10% to 90%.
Analysis
We solved this decision analysis model on the basis of a categorical outcome of survival and death. Survival was assigned a value of 1 and death was given a value of 0. Sensitivity analyses were completed by independently changing the probabilities throughout the range of values Table 1 that were determined to be biologically plausible, on basis of the available literature.
RESULTS
Baseline Analysis
After the baseline probabilities were placed into the decision analysis tree as described above, the tree was solved to determine whether there was an improvement in survival with palivizumab prophylaxis in BMT patients. The results revealed that there is a 10% increase in survival in BMT patients who receive palivizumab when compared with those who do not receive the antibody. The absolute survival rate increased from 83% to 92%. Using these survival rates, the number needed to treat would be 12, meaning that a practitioner would need to treat 12 children to save 1 post-BMT child from dying from RSV-related lung disease.
Sensitivity Analyses
To determine whether this improvement in mortality was robust over the range of biologically plausible probabilities, sensitivity analyses were completed for each of the 5 probabilities across the range of values described in Table 1 .
To determine the sensitivity of the probability of being exposed to RSV, a sensitivity analysis was performed across the range from a 20% to 60% probability. Throughout this range, prophylaxis with palivizumab demonstrated an increased survival (Fig. 2) .
To examine the sensitivity of this model to changes in the probability of hospitalization with RSV disease after receiving palivizumab, we performed a sensitivity analysis across the range from 10% to 40%. Treatment with palivizumab is dominant until the point of a 40% chance of being hospitalized, at which point the decision approaches indifference (Fig. 3) . This threshold is intuitive, as the mechanism for decreased mortality in this decision analysis model is decreased hospitalization from RSV LRT disease after palivizumab prophylaxis, and 40% approaches the basic rate of hospitalization in BMT patients who did not receive treatment.
Prophylaxis with palivizumab demonstrated an increased survival throughout the biologically plausible range of values for the probability of hospitalization from RSV infection without prophylaxis with palivizumab (Fig. 4) .
The final sensitivity analysis examined the range of probabilities of survival after RSV infection (Fig. 5) . Clearly, the treatment arm is preferred throughout the entire range of these biologically plausible values. 
DISCUSSION
On the basis of the decision analysis model, it seems that prophylaxis with palivizumab in the high-risk population of pediatric BMT patients leads to a decrease in mortality after an infection with RSV. Although these results are based on mathematical modeling of a complex pathophysiologic process, given both the improved outcomes in other high-risk patients who receive prophylaxis with palivizumab and the severe clinical course of RSV LRT in BMT patients, the use of palivizumab seems sensible. On the basis of our modeling, a practitioner would be required to treat 12 BMT children to save one life from RSV-related death.
Decision analysis is a systematic approach that can be used to determine the value of various decision options. Although initially developed as a tool to assist clinicians in determining the most favorable treatment plan for an individual patient, 13, 14 this methodology is being increasingly used to assist in developing policies and treatment options for larger cohorts of subjects in whom a randomized controlled clinical trial is unlikely to be performed. Although straight decision analyses such as employed in this study are common, this technique is also being used frequently for determining the most cost effective approach to a complex medical question.
Viral infections such as RSV, in immunosuppressed subjects, can lead to substantial morbidity and mortality. The omnipresent nature of RSV during the winter months poses a significant risk to immunocompromised hosts. Moreover, the problem is exacerbated by the fact that there are presently no antiviral therapies that have proven benefit in well-designed randomized controlled trials. Although engraftment status may be important to the development of RSV infections, no correlation has been determined between engraftment status and outcome, and we therefore not used in the decision analysis model. 11, 15 Palivizumab is a humanized murine monoclonal anti-F glycoprotein immunoglobulin G1 antibody against RSV. It is now considered standard-of-care in high-risk children. However, perhaps owing to the cost of this antibody and the inconvenience that is associated with a monthly injection that is required throughout the RSV season and the large sample size that would be required, no randomized controlled trials have been performed to date in the immunocompromised population. For this reason, we chose to perform a decision analysis model to address this question. By using probabilities on basis of the published epidemiologic and clinical trials, we are able to formulate predictions as to the effectiveness of this therapy in a patient population in which it has not previously been studied.
There are some limitations to this type of analysis. First, it is necessary to rely on the published data that are available, and to make inferences in applying those data to our target population. We chose to use the incidence of RSV exposure in normal healthy children to determine our first probability. This choice may have biased our results favoring a more positive effect than may actually exist. However, RSV is spread by both air-born and contact routes and has the potential to live on inanimate surfaces for hours, which likely leads to the high exposure rates seen during each winter season. Moreover, our sensitivity analysis revealed a benefit even when using a 20% exposure rate, which is substantially less than the general population. It is presently unknown whether there are differences in the incidence of exposure, the severity of illness, or the effect of the antibody across the wide age range of pediatric BMT patients. A second limitation of our design is that we were required to determine probabilities of hospitalization both in the presence and absence of palivizumab on basis of the literature not directly applicable to our population of interest. However, the estimates used were based on reliable data and were determined by formal meta-analysis techniques. Additionally, sensitivity analyses demonstrated the robustness of our model. Also, a relatively conservative rate of hospitalization was chosen for these children, which would bias the results toward a negative study as compared with a higher rate of hospitalization. Third, to remain conservative in our findings, it was assumed that treatment with palivizumab did not reduce the severity of RSV LRT disease once a child was hospitalized. This assumption was based on the finding of no difference in disease severity with palivizumab treatment in previously premature infants with bronchopulmonary dysplasia. 16 If this antibody results in a decreased mortality among hospitalized patients, the benefit would be even more favorable. Finally, without a clinical trial, it is truly impossible to determine if palivizumab will have the same protective benefit among pediatric BMT patients as in other high-risk groups. Interestingly, palivizumab was found to be highly effective in reducing pulmonary complications in an immunocompromised animal model, although multiple doses were necessary. 17 This result lends biologic credence to our mathematical findings. Moreover, a recent phase 1 study demonstrated the safety of palivizumab in recipients of hematopoietic stem cell transplants. 18 In conclusion, LRT infections secondary to RSV are a serious and life-threatening complication among pediatric BMT patients. Palivizumab is an effective prophylactic therapy against this virus that has been demonstrated to be beneficial in other cohorts of patients at high-risk for RSV disease. Our decision analysis model suggests that a decrease in mortality in pediatric BMT patients will occur with the addition of palivizumab to protect against severe RSV disease. In light of these findings, supported by animal studies and a phase 1 trial demonstrating safety among BMT patients, clinicians should consider the use of this therapy in pediatric BMT patients until a well-designed, randomized controlled trial is performed.
